Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy

Affiliations

¹ Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
² Takeda Pharmaceutical Company Ltd., Osaka, Japan.
³ Health Sciences University of Hokkaido, Hokkaido, Japan.

Comment

Kazunari Murakami et al. Gut. 2017 Feb.

. 2017 Feb;66(2):386.

doi: 10.1136/gutjnl-2016-312011. Epub 2016 May 3.

¹ Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
² Takeda Pharmaceutical Company Ltd., Osaka, Japan.
³ Health Sciences University of Hokkaido, Hokkaido, Japan.

No abstract available

Keywords: ANTIBIOTIC THERAPY; CLINICAL TRIALS; HELICOBACTER PYLORI INFECTION.

Comment on

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Murakami K, et al. Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2. Gut. 2016. PMID: 26935876 Free PMC article. Clinical Trial.
Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues.
Graham DY. Graham DY. Gut. 2017 Feb;66(2):384-386. doi: 10.1136/gutjnl-2016-311796. Epub 2016 Apr 7. Gut. 2017. PMID: 27056876 Free PMC article. No abstract available.